What Two River does

Two River, LLC is a privately held life science merchant bank founded in September 2004 by Joshua Kazam, David Tanen, and Arie Belldegrun, and headquartered at 689 Fifth Avenue, 12th Floor, New York, NY 10022. The firm specializes in founding, building, and incubating biotechnology companies, partnering with scientific founders and experienced management teams to create, finance, and operate companies in oncology, immunotherapy, and synthetic/chemical biology. Two River invests its own capital alongside founders, then provides ongoing operational capability, corporate development, transaction support, regulatory and product development guidance, and leadership recruitment through the life of each portfolio company. The firm is led by Chairman & Partner Arie Belldegrun, MD (founder of Kite Pharma, Allogene, Kronos Bio) and partners Joshua Kazam and David Tanen, supported by Operating Partner Chris Wilfong, Principal Nicole van de Leuv, CFO Sean Algeo, Venture Partner David Chang (President & CEO of Allogene, former CMO of Kite), and academic advisors Owen Witte, MD and James Economou, MD, PhD.

Two River does not sell products or services to external customers; its revenue is generated from equity ownership in portfolio companies, realized primarily through strategic acquisitions and IPOs. Documented exits include Kite Pharma's $11.9B sale to Gilead in 2017, Neogene Therapeutics' acquisition by AstraZeneca in January 2023, and Candid Therapeutics' up to $2.2B sale to UCB announced in May 2026. Co-founded portfolio companies that remain active include Allogene Therapeutics (allogeneic CAR T for cancer and autoimmune disease) and Kronos Bio (small molecule microarrays for recalcitrant cancer targets). Two River operates within the Bellco Health ecosystem alongside Vida Ventures (a next-generation life sciences VC firm co-founded by Kazam and Belldegrun in 2018), with affiliated platforms including Breakthrough Properties (life science real estate) and Symbiotic Capital (healthcare credit).

The firm functions as a low-headcount (11-50 employees), high-conviction company creation platform, sourcing assets globally (including from China) and operating a co-creation model with Vida Ventures that produced Candid Therapeutics. It does not disclose AUM, fund size, revenue, or employee count beyond the 11-50 range, and is structured as a limited liability company domiciled in New York.

Name

Two River

Legal name

Two River, LLC

Website

https://tworiver.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Two River is a privately held New York-based life science merchant bank that founds, finances, and operates biotechnology companies, partnering with scientific founders in oncology, immunotherapy, and synthetic/chemical biology, and generating returns through equity stakes in portfolio company exits.

Ownership category

akta.pro rank

Product category

Life Science Merchant Banking

NAICS

Management of Companies and Enterprises (551)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Life science investment
• Biotechnology company building
• Venture capital services
• Biotech incubation services
• Pharmaceutical company creation

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Investment Returns: Two River generates returns through equity ownership in portfolio companies they found and develop. Successful exits include Kite Pharma (acquired by Gilead for $11.9B), Neogene Therapeutics (acquired by AstraZeneca), and Candid Therapeutics (acquired by UCB for up to $2.2B).

Go-to-market motion1 record

Marketing channels2 records

Core offering

Two River partners with scientific founders and experienced management to create, finance, and operate outstanding companies in the life science sector. The firm founds and invests its own capital into companies with strong intellectual property and proven leadership teams, working closely with founders on product development, regulatory and corporate strategy, and day-to-day business operations.

Product overview

Two River is a life science consulting and investment firm that builds companies rather than software products. The company focuses on founding, building and incubating biotechnology companies through innovative science and strategic partnerships. The core offering consists of company creation and investment services combined with operational support, corporate development, transaction support, and leadership recruitment for portfolio companies. Key portfolio companies include Allogene Therapeutics (allogeneic CAR T therapy for cancer and autoimmune disease), Candid Therapeutics (T-cell engagers for autoimmune diseases, acquired by UCB for $2.2B), Kronos Bio (small molecule therapies targeting transcription factors in oncology), and Neogene Therapeutics (personalized TCR therapies, acquired by AstraZeneca). Affiliates include Vida Ventures (life sciences VC firm) and Symbiotic Capital (healthcare credit firm).

Differentiator

Problem solved

Functional benefit

Products and services

• Company Creation & Investment Services Service for scientific founders and experienced management teams in the life science sector, in which Two River partners with founders to create, finance, and operate new biotechnology companies by investing its own capital alongside strong intellectual property and proven leadership teams.
• Portfolio Company Support Services Ongoing support service to Two River's portfolio companies, providing capital, operational capability, corporate development and transaction support, and leadership recruitment and mentorship to accelerate research and clinical development.

Quantifiable outcome

• Kite Pharma acquired by Gilead for $11.9 billion in 2017
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Ten partnerships are on record, tiered flagship, core and minor.

• Vida VenturesflagshipStrategic or Co-development Partner · 3 May 2026Two River and Vida Ventures, both part of the Bellco Health ecosystem, have an established track record of company creation together. They played central roles in founding and developing Candid Therapeutics, formed through the merger of TRC 2004 (founded by Two River) and Vignette Bio. Vida Ventures is a next-generation life sciences investment firm co-founded by Joshua Kazam.
• Neogene TherapeuticscoreStrategic or Co-development Partner · 1 January 2023Two River co-founded Neogene Therapeutics, which was acquired by AstraZeneca in 2023. The company pioneered next-generation TCR therapies for solid tumors. Chris Wilfong held interim senior leadership roles.
• Bellco HealthflagshipStrategic or Co-development PartnerTwo River is part of the Bellco Health ecosystem, which includes Vida Ventures. Bellco Capital provides strategic alignment and access to resources for company creation and investment activities.
• Allogene TherapeuticscoreStrategic or Co-development PartnerTwo River co-founded Allogene Therapeutics, a biotechnology company developing allogeneic CAR T-cell therapy for cancer and autoimmune diseases. David Tanen co-founded and served as Corporate Secretary; Arie Belldegrun serves as Executive Chairman.
• Kite PharmacoreStrategic or Co-development PartnerCo-founded by Joshua Kazam and David Tanen; acquired by Gilead Sciences in 2017 for $11.9 billion. Chris Wilfong served as co-founder and held interim senior leadership roles. This was a flagship exit demonstrating Two River's company creation capabilities.
• Kronos BiocoreStrategic or Co-development PartnerArie Belldegrun serves as Founding Chairman. Kronos Bio is dedicated to research and development of first-in-class therapies targeting historically recalcitrant cancer targets using small molecule microarray platform.
• Breakthrough PropertiescoreStrategic or Co-development PartnerJoshua Kazam is a co-founder and Director. Breakthrough Properties is a life science real estate development company leveraging cross-sector collaboration to deliver environments that foster innovation. Raised $1 billion for life science real estate investments.
• Symbiotic CapitalcoreStrategic or Co-development PartnerJoshua Kazam serves as an advisor. Symbiotic Capital is a global healthcare credit firm structuring and originating credit solutions to healthcare companies supporting scientific innovation.
• Cell Design LabsminorStrategic or Co-development PartnerCell Design Labs is a private biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other diseases.
• Candid TherapeuticsflagshipStrategic or Co-development PartnerTwo River founded TRC 2004 which merged with Vignette Bio to form Candid Therapeutics. Two River sourced one of Candid's lead assets from China. Candid was acquired by UCB for up to $2.2 billion in 2026.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Vida Ventures: Next-generation life sciences investment firm co-founded by Joshua Kazam and Arie Belldegrun. Operates within the Bellco Health ecosystem alongside Two River and has co-created companies (e.g., Candid Therapeutics), making it the most direct peer in model and team overlap.
• ARCH Venture Partners: Long-tenured life sciences venture firm that founds and builds biotech companies from breakthrough science. Closely comparable to Two River in company-creation model, principal risk-taking, and focus on oncology and platform technologies.
• Flagship Pioneering: Bioplatform company-creation firm that originates and incubates new therapeutic ventures. Comparable to Two River through its in-house science-to-company engine and reliance on principal-founder-driven biotech launches.
• Atlas Venture: Early-stage life sciences venture firm that builds biotech companies from inception through clinical proof-of-concept. Mirrors Two River's company-creation model and stage focus on emerging therapeutics.
• Third Rock Ventures: Healthcare venture firm that founds and builds biotech companies around transformative science. Highly comparable to Two River in team-led incubation, oncology focus, and operational involvement with portfolio companies.
• Versant Ventures: Healthcare-focused venture firm with a dedicated company-creation engine (e.g., Inception Sciences). Comparable to Two River through its in-house biotech origination approach and therapeutic breadth.
• 5AM Ventures: Early-stage life sciences venture firm that creates and invests in biotech companies. Comparable to Two River in its science-driven, founder-partnered approach to building therapeutic platforms.

Broad incumbents

• OrbiMed: Largest dedicated healthcare investment platform across venture, growth, and credit. Comparable to Two River in life-sciences focus but operates at meaningfully greater scale and broader stage range.
• Baker Bros. Advisors: Long-tenured, science-driven biotech-focused investment manager. Comparable to Two River in deep therapeutic expertise and conviction-driven positions across public and private life sciences.
• New Enterprise Associates (NEA) — Healthcare: Diversified venture firm with a large healthcare practice investing across biotech stages. Comparable to Two River in company-creation activity but with broader sector coverage and larger fund vehicles.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments25 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Two River